RxDoctor Payments Data

Shyamanga Borooah, MD

Cornea and External Diseases Specialist · San Diego, CANPI 1275165102

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Amgen. That places this record below the midpoint for cornea and external diseases specialist clinicians in CA, where the typical reported total is $4,024.

$50in general payments, 2019–2025

Across 2 payments — averaging $25.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$50
$472,203in research payments, 2019–2025

Across 17 payments — averaging $27,777 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$472K

What the payments were for

  • Food & beverage$50100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen2$50

How this compares

$50 in reported general payments places this provider in the 0th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$451,074
Medicare patients
386
Services billed
5,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Difluprednate14$1,995
Prednisolone Acetate21$504

Paid to pharmacies, not to this prescriber.

Other cornea and external diseases specialist in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →